Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

Rayaldee significantly increased 25D levels

Study Design

Mean 25D levels over time in clinical trials2*

Increased 25D levels were associated with corresponding increases in 1,25D levels1

*Mean data from patient clinical trials do not guarantee individual results.

Patients achieving target 25D levels (≥30 ng/mL) at week 261

Average steady-state 25D levels: ≥50 ng/mL1